| 复发性卵巢癌的药物治疗及进展 |
| |
| 引用本文： | 王雪,张广美,何征秦.复发性卵巢癌的药物治疗及进展[J].中国现代医学杂志,2021,31(1):38-44. |
| |
| 作者姓名： | 王雪 张广美 何征秦 |
| |
| 作者单位： | （哈尔滨医科大学附属第一医院 妇产科，黑龙江 哈尔滨 150001） |
| |
| 摘 要： | 卵巢癌在女性妇科肿瘤中死亡率第一，且复发率高。复发性卵巢癌无法治愈，目前复发性卵巢
癌的治疗以改善患者生活质量，延长患者无进展生存期及总生存期为目的。分子靶向治疗复发性卵巢癌是
研究热点，靶向药物包括抗血管生成药物、聚二磷酸腺苷核糖聚合酶抑制剂及免疫检查点抑制剂。该文重
点对复发性卵巢癌的药物治疗进展进行综述。
|
| 关 键 词： | 卵巢肿瘤 抗血管生成药物 聚二磷酸腺苷核糖聚合酶抑制剂 免疫检查点抑制剂 |
| 收稿时间： | 2020/11/10 0:00:00 |
Drug treatment and research progress of recurrent ovarian cancer |
| |
| XueWang,Guang-mei Zhang,Zheng-qin He.Drug treatment and research progress of recurrent ovarian cancer[J].China Journal of Modern Medicine,2021,31(1):38-44. |
| |
| Authors: | XueWang Guang-mei Zhang Zheng-qin He |
| |
| Institution: | (Department of Gynecology, The First Affiliated Hospital of Harbin Medical University,
Heilongjiang, Harbin 150001, China) |
| |
| Abstract: | Ovarian cancer has the highest mortality among female gynecological tumors and has a
high recurrence rate. There is no cure for recurrent ovarian cancer, and the current treatment of recurrent
ovarian cancer is aimed at improving the quality of life of patients, prolonging progression-free survival
and overall survival. Molecular targeted therapy for recurrent ovarian cancer is a research hot-spot.
Targeted drugs include anti-angiogenesis drugs, PARP inhibitors and immune checkpoint inhibitors. This
review focuses on the advances of drug therapy for recurrent ovarian cancer. |
| |
| Keywords: | ovarian neoplasms anti-angiogenesis drugs poly (adp-ribose) polymerase inhibitors immune checkpoint inhibitors |
|
| 点击此处可从《中国现代医学杂志》浏览原始摘要信息 |
| 点击此处可从《中国现代医学杂志》下载免费的PDF全文 |
